Inclusion Criteria:

Participants must meet all of the following criteria:

• Male or Female patients 18 years and older.
• Patient with a diagnosis of chronic myelogenous leukemia in chronic phase
• Within 6 months of initial diagnosis.
• Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.

Exclusion Criteria:

• Late chronic phase, accelerated phase or blastic phase
• Taking any other investigational agents within 28 days of starting the study
• If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.
• Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.
• If patients have heart problems or complications
• Pregnant or breast-feeding females
• Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.
• Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
• Diagnosis of human immunodeficiency virus (HIV) infection.
• Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.
• Patient previously received radiotherapy to greater than 25% of the bone marrow.
• Patient had a major surgery within 4 weeks prior to study entry